CLX trades 14.9% below Wall Street's consensus target of $100.11.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLX achieves its forward estimates and maintains a stable P/E multiple of 15.8x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, The Clorox Company (CLX) has a Wall Street consensus price target of $100.11, based on estimates from 29 covering analysts. With the stock currently trading at $87.15, this represents a potential upside of +14.9%. The company has a market capitalization of $10.54B.
Analyst price targets range from a low of $83.00 to a high of $127.00, representing a 44% spread in expectations. The median target of $98.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 3 analysts rating the stock as a Buy or Strong Buy,21 rating it Hold, and 5 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CLX trades at a trailing P/E of 13.4x and forward P/E of 15.8x. Analysts expect EPS to grow +14.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $86.89, with bear and bull scenarios of $54.74 and $114.48 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CHDChurch & Dwight Co., Inc. | $22.8B | $96.13 | $108.88 | +13.3% | Buy | 25.4x | 34 |
 SPBSpectrum Brands Holdings, Inc. | $2.0B | $88.02 | $97.60 | +10.9% | Buy | 13.8x | 21 |
 ENREnergizer Holdings, Inc. | $1.5B | $22.35 | $20.00 | -10.5% | Hold | 6.8x | 24 |
 RCKYRocky Brands, Inc. | $340M | $45.15 | $50.00 | +10.7% | Buy | 9.1x | 4 |
 PGThe Procter & Gamble Company | $345.1B | $148.22 | $157.78 | +6.4% | Buy | 21.2x | 53 |
 KMBKimberly-Clark Corporation | $32.8B | $98.91 | $112.25 | +13.5% | Hold | 13.3x | 31 |
 COTYCoty Inc. | $2.4B | $2.67 | $2.67 | +0.0% | Hold | 12.4x | 33 |
 EPCEdgewell Personal Care Company | $1.3B | $27.96 | $29.83 | +6.7% | Hold | 14.5x | 17 |
 PBHPrestige Consumer Healthcare Inc. | $2.3B | $47.73 | $81.67 | +71.1% | Buy | 10.4x | 17 |
 WMTWalmart Inc. | $877.8B | $110.12 | $128.84 | +17.0% | Buy | 38.1x | 66 |
Quick answers to the most common questions about buying CLX stock.
The Clorox Company (CLX) has a consensus 12-month price target of $100.11, implying 14.9% upside from $87.15. The 29 analysts covering CLX see moderate appreciation potential.
CLX has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is leaning bearish, with 5 Sell/Strong Sell ratings. The consensus 12-month price target of $100.11 implies 14.9% upside from current levels.
With a forward P/E of 15.7852x, CLX trades at a relatively low valuation. The consensus target of $100.11 implies 14.9% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $127 for CLX, while the most conservative target is $83. The consensus of $100.11 represents the median expectation. Our quantitative valuation model projects a bull case target of $114 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CLX is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 21 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLX stock forecast based on 29 Wall Street analysts shows a consensus price target of $100.11, with estimates ranging from $83 (bear case) to $127 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $87, with bear/bull scenarios of $55/$114.
Our quantitative valuation model calculates CLX's fair value at $87 (base case), with a bear case of $55 and bull case of $114. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.
CLX trades at a forward P/E ratio of 15.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 13.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CLX, with a "Hold" consensus rating and $100.11 price target (14.9% upside). 3 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLX analyst price targets range from $83 to $127, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $100.11 consensus represents the middle ground. Our model's $55-$114 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.